

Open Peer Review on Qeios

HDAC Inhibitor CXD101

National Cancer Institute

Source

National Cancer Institute. <u>HDAC Inhibitor CXD101</u>. NCI Thesaurus. Code C112177.

A novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Although the exact therapeutic mechanism of action for CXD101 is not known, oral administration of this agent should inhibit the catalytic activity of HDAC, which results in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. HDAC, a family of enzymes upregulated in many tumor types, deacetylates chromatin-associated histone proteins.

Qeios ID: QOM5M5 · https://doi.org/10.32388/QOM5M5